

TUBERCULOSIS PROFILE:

INDIA



@SUDARSHAN L S

Estimates of TB burden*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	2 820 000 (2 390 000-3 280 000)	199 (169-231)
HIV-positive TB incidence	48 000 (40 000-55 000)	3.4 (2.8-3.9)
MDR/RR-TB incidence**	110 000 (89 000-140 000)	8 (6.3-9.6)
HIV-negative TB mortality	331 000 (237 000-440 000)	23 (17-31)
HIV-positive TB mortality	11 000 (8 100-14 000)	0.76 (0.57-0.99)

Estimated proportion of TB cases with MDR/RR-TB*, 2022

New cases	2.5% (2.3-2.7)
Previously treated cases	13% (12-14)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2022	80% (69-94)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2022	12% (8-17)

TB case notifications, 2022

Total new and relapse	2 255 641
- % tested with rapid diagnostics at time of diagnosis	33%
- % with known HIV status	96%
- % pulmonary	75%
- % bacteriologically confirmed ^	64%
- % children aged 0-14 years	5%
- % women (aged ≥15 years)	37%
- % men (aged ≥15 years)	58%
Total cases notified	2 402 024

TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive	37 578	1.7%
- on antiretroviral therapy	37 216	99%

Drug-resistant TB care**, 2022

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	76%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	80%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	52 029
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^^	48 801
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	12 382
Patients started on treatment - pre-XDR-TB or XDR-TB ^^^	11 620
MDR/RR-TB cases tested for resistance to any fluoroquinolone	23 611

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	87%	1 905 759
Previously treated cases, excluding relapse, registered in 2021	84%	147 747
HIV-positive TB cases registered in 2021	78%	33 029
MDR/RR-TB cases started on second-line treatment in 2020	69%	40 168
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020	64%	8 950

TB preventive treatment, 2022


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	22% (22-23)

Funding for TB

Funding for TB, 2022 (US\$ millions)	301
- % domestic funding	61%
- % international funding	39%
National TB budget, 2023 (US\$ millions)	671
- Funding source, domestic	81%
- Funding source, international	19%
- Unfunded	0%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




HIV-negative TB mortality

(Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2022

(Number)



Cases attributable to five risk factors, 2022


(Number)



Funding for TB

(US\$ millions)

domestic international





Thank
you

